RePORT International Resources

This webinar explores mycobacterial diagnostic tools and their applications in TB prevention and treatment. Learn to effectively use and interpret Tuberculin Skin Tests (TSTs), interferon-gamma release assays (IGRAs), and cultures for diagnosing latent TB infection (LTBI) and active TB disease. Case studies will highlight real-world challenges and best practices for leveraging these tools in clinical practice.

Tuberculosis (TB) in pregnancy poses serious risks to both mother and fetus if not promptly diagnosed and managed. This webinar covers key aspects of TB diagnosis, treatment, and complications during pregnancy. Participants will also be introduced to the TB Pregnancy Toolkit and other resources to support effective care for pregnant patients.

This webinar explores how molecular testing and imaging support TB diagnosis by enhancing accuracy, speeding detection, and guiding effective treatment decisions. This course is designed for allied health professionals, nurses, nurse practitioners, physicians, physician assistants, resident/fellows, and healthcare professionals working in a public healthcare setting. Learning Objectives Identify essential tools for TB diagnosis Describe molecular testing methods Explain imaging roles in TB diagnosis

Please refer to the website for the details on deadline, pricing, courses that are offered

McGill TBcentre - many webinars and mini courses (all prerecorded)

TSTin4D and IGRAin4D are both are decision aids providing information about the likelihood of developing TB disease, dying from TB, as well as post-TB disability, in the next 20 years in a person with a positive tuberculin skin test or a positive Interferon gamma release assay and a known risk factor. This also provides information on the potential benefits and risks of TB preventive therapy. Also added is information for the person considering whether to accept TB preventive therapy, including a handout that includes predictions for them, and some basic information about TB prevention.

This Notice of Funding Opportunity (NOFO) invites eligible academic or research institutions to apply for funding support to purchase latest scientific equipment that will enhance and modernize research-supporting operations of existing shared biomedical research facilities. Targeted are laboratory research core facilities, animal research facilities, and other similar shared-use research spaces. The goal of this NOFO is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficiency of their operations. The NOFO does not support the purchase of scientific research instruments or their components, nor components of building-level infrastructure equipment that indirectly support research activities.

This course requires about 40 total hours to complete. It is self-paced, has open enrollment, and can be accessed for 60 days.

The Work Programme 2026 has been revised to include a new funding scheme, ERC Plus Grants, which will support outstanding researchers from Europe and anywhere in the world with bold ideas and a vision for transformative research that goes beyond the scope of existing ERC programmes.

Applications for the third round of the New York State Biodefense Commercialization Fund are now closed. Please check back for updates on the program. The $40 million Biodefense Commercialization Fund was created to encourage and accelerate the development and commercialization of solutions for serious infectious disease threats, including COVID-19 and its variants, while fostering the creation of new life science businesses and supporting industry growth. The Fund has offered grants to startup companies and academic institutions that are developing promising diagnostics, vaccines, therapeutics, and such other innovations as epidemiological surveillance tools, environmental controls, and clinical care advances that address or mitigate infectious disease threats. For the current application period, New York State seeks applications focusing on the specific areas of interest: - Novel platforms for development of rapid Point-of-Care (POC) diagnostics (examples include, but are not limited to, CRISPR and/or Isothermal-based platforms) with priority given to POC diagnostics that can perform as well as or better than existing lab tests. - Processes that integrate easy-to-use sample preparation and allow for access in low resourced settings. - Novel tools for sequencing and serology-based tests that support infectious disease and pathogen surveillance

The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Notice of Funding Opportunity (NOFO) invites SBIR grant applications from SBCs to support later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and which will require eventual Federal regulatory approval/clearance. The purpose of this NOFO and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Projects proposed under this NOFO MUST be relevant to the NHLBI mission (see B. Scientific/Technical Scope). This NOFO is specifically intended to benefit clinical practice by accelerating the commercialization of novel products that require ultimate approval/clearance by a Federal regulatory agency. This NOFO will give competitive preference and funding priority to applications deemed likely to result in a clinically-relevant commercial product as indicated by the applicant’s ability to secure independent third-party investor funds that equal or exceed the requested NHLBI funds, and competitive preference and funding priority to applications that show a strong potential for clinically relevant commercial products, as evidenced by the applicant’s ability to secure independent third-party investor funds equal to or exceeding the total requested costs. Please refer to the website for detail announcement and key dates.

The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Version 2.1 used in … clinical trials for safety data reporting to maintain accuracy and consistency in the evaluations of SAEs.

This document provides a detailed list of essential documents” (regulatory documents). “The purpose and/or description of these documents is/are given with a recommended location where they should be filed during the conduct of a clinical trial.

NIH NIAID - Grants and Fundings - Searchable Database

Advancing TB research through open-access, multi-domain, global TB data and tools.

The NIH Extramural Nexus is the NIH's official platform for updates on grants policies, application processes, and funding news. Hosted within the NIH Grants & Funding website, it serves as a centralized resource for researchers, administrators, and institutions navigating the NIH extramural research landscape. The platform offers timely information on policy changes, application tips, and new resources, ensuring the research community stays informed and compliant with NIH requirements.

Learn the basics with NIH Grants Process: A Walk-Through for Beginners Tune in for answers to your questions in the NIH Expert Q&A Panel: Part 1 Test your knowledge with Submission Policies: You Make the Call More questions and answers in the NIH Expert Q&A Panel: Part 2 Take our panelists’ advice: Grant Application Tips from NIH Experts

The material in this series will increase your awareness of work, communication, and conflict styles, using examples highly relevant to research environments. The series is helpful for trainees and fellows at all levels. The series is also helpful for fellows who supervise others and want to develop strong mentoring skills for the future. There are three sessions in the series; each is offered once in the fall and spring. While it is best to attend the entire series, you may attend individual sessions. Trainees and fellows who complete all three units of the Workplace Dynamics Series will receive a certificate of completion. All three units of this series are required for participation in the OITE Management Short Course offered each spring.

By accepting a grant award, recipients agree to comply with the requirements in the NIH Grants Policy Statement unless the notice of award states otherwise. Please refer to the website for specific policy topic pages for additional context and resources.

To advance science and improve human health, NIH makes the peer-reviewed articles it funds publicly available on PubMed Central. The 2024 NIH Public Access Policy requires Author Accepted Manuscripts accepted for publication in a journal, on or after July 1, 2025, to be submitted to PubMed Central upon acceptance for publication, for public availability without embargo upon the Official Date of Publication